Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

Maxygen: Bayer $30 Million Payment Likely In 2012
Apsara Biotechnology Research • BAYZF.PK, MAXY • Wed, May 2, 2012, 09:13 ET
Reasons To Be Bullish On Acacia Research Corporation
Tactical Investor • FNGN, GCA, NES • Tue, Apr 3, 2012, 11:48 ET
Array Biopharma Inc. Offers Value And Upside Potential With Its Many Drugs
Roy Manning III • RHHBY.OB, ITMN, AZN • Mon, Apr 2, 2012, 15:18 ET
Acacia Research Corporation: A Long-Term Growth Play?
Tactical Investor • ABB, NES, TEF • Fri, Mar 9, 2012, 13:55 ET
Odyssey Marine Exploration Finally Presents Opportunity
Greatstockpix • OMEX • Wed, Mar 7, 2012, 09:55 ET
Maxygen: A Biotech Play With Low Downside - Part 2
Apsara Biotechnology Research • AMGN, MAXY • Fri, Mar 2, 2012, 11:47 ET
Acacia Research: Another Acquisition In The Pipeline
Growth Stock Insider • ACTG • Thu, Mar 1, 2012, 10:12 ET
Maxygen: A Biotech Play With Low Downside - Part 1
Apsara Biotechnology Research • MAXY • Thu, Mar 1, 2012, 06:08 ET
Gen-Probe Looking To New Launches To Drive Momentum
Stephen Simpson • BDX, CPHD, QGEN • Tue, Feb 14, 2012, 20:58 ET
Odyssey Marine Exploration: The Sum Of The Mutually Exclusive Options
South of Wall Street • OMEX • Mon, Feb 6, 2012, 07:24 ET
The Best Way To Play Odyssey Marine And Shipwreck Exploration
Jaded Consumer • OII, SUBCY.PK, OMEX • Fri, Feb 3, 2012, 12:09 ET
Odyssey Marine Exploration: The Perfect Stock For A Choppy Market
Jared Sleeper • OMEX • Thu, Dec 22, 2011, 02:59 ET
Landauer: Accretive Is A 4 Letter Word
Frank Voisin • LDR • Wed, Dec 14, 2011, 09:30 ET
The Recent Drop In Albany Molecular's Stock Price May Be Overdone
Paul Nouri • LLY, AMRI • Thu, Nov 10, 2011, 10:41 ET
Gen-Probe Post-Earnings Pattern: Evenly Mixed For Longs And Shorts
Midnight Trader • GPRO • Wed, Nov 2, 2011, 10:29 ET
Record Silver Booty For Odyssey Marine Exploration
Wall Street Strategies • SLV, OMEX • Tue, Sep 27, 2011, 14:58 ET
Odyssey Marine: Whether The $280M Gairsoppa Shipwreck Recovery Is Imminent
Daniel Wilson • OMEX • Tue, Sep 20, 2011, 10:38 ET
Array Represents a Great Opportunity for Very Patient Investors
Prohost Biotech • ARRY • Wed, Aug 17, 2011, 06:07 ET
Array BioPharma's Cancer Deal Expands Its Coffers
M. E. Garza • RHHBY.OB, AMGN, NVS • Tue, Aug 9, 2011, 11:41 ET
S&P Downgrades USA: Buy Odyssey Marine Exploration
LightseedVC • OMEX • Mon, Aug 8, 2011, 04:28 ET
Odyssey Marine Is Undervalued
Daniel Wilson • OMEX • Wed, Aug 3, 2011, 16:03 ET
Gen-Probe's Post-Earnings Pattern Offers Something for Longs and Shorts
Midnight Trader • GPRO • Thu, Jul 28, 2011, 13:48 ET
Bottom Bounce for Array BioPharma
M. E. Garza • ARRY • Wed, Jun 29, 2011, 09:17 ET
Landauer: A Steadily Increasing Dividend Nearing a 4% Yield
Clay King • LDR • Wed, Jun 8, 2011, 11:24 ET
Odyssey Marine: The Ultimate Event-Driven Small Cap
BlueCut Capital • OMEX • Sun, May 29, 2011, 08:23 ET
Cleveland Biolabs: Shares Could Head Higher After Quake Confusion
M. E. Garza • CBLI • Tue, Mar 22, 2011, 12:14 ET
Looking for Squeeze Pressure on Cleveland BioLabs
M. E. Garza • CBLI • Tue, Mar 15, 2011, 12:36 ET
Jumping on the Cleveland Biolabs Bandwagon
M. E. Garza • CBLI • Wed, Feb 2, 2011, 10:48 ET
Myriad: 2Q EPS In-Line, Beats on Revenues
Zacks Investment Research • MYGN • Fri, Jan 28, 2011, 12:12 ET
Cleveland Biolabs Anti-Cancer Effect Brings Potential Value
M. E. Garza • CBLI • Fri, Jan 21, 2011, 15:17 ET
Why Odyssey Marine Is Worth Exploring
BlueCut Capital • OMEX • Mon, Jan 10, 2011, 03:24 ET
New Orphan Drug Status May Boost Cleveland BioLabs Shares
M. E. Garza • CBLI • Tue, Nov 30, 2010, 20:19 ET
Cleveland BioLabs' Unfounded Fear of Dilution
M. E. Garza • CBLI • Sun, Oct 17, 2010, 09:20 ET
Investment Risk in Cleveland BioLabs Has Been Wiped Off the Table
M. E. Garza • CBLI • Sun, Oct 3, 2010, 03:54 ET
Interview: Cleveland BioLabs CEO Discusses Recent Developments, Milestones Ahead
M. E. Garza • CBLI • Fri, Aug 27, 2010, 08:09 ET
Myriad Genetics: Growing Medical Diagnostics Franchise at Value Price
SeekingValue • MYGN • Wed, Jun 30, 2010, 11:32 ET
Myriad Gene Patents Ruling Unsettles U.S. Biotech Industry
The Burrill Report • MYGN • Mon, Apr 5, 2010, 03:50 ET
Biotech, Internet, Lead Future of Technology's Mind Blowing Innovation
John Mauldin • CRA • Sun, Mar 7, 2010, 05:13 ET
Is Cleveland BioLabs Ready to Move Higher?
M. E. Garza • CBLI • Wed, Feb 24, 2010, 09:48 ET
Closing Myriad Genetics After Oppenheimer Analyst Brings Out the Hammer
TraderMark • MYGN • Tue, Jan 12, 2010, 13:22 ET
Myriad Genetics: Starting to Outperform
optionMONSTER • MYGN • Wed, Dec 30, 2009, 10:23 ET
Restarting Myriad Genetics
TraderMark • MYGN • Thu, Dec 24, 2009, 06:56 ET
FDA Approves Gen-Probe Assay
Zacks Investment Research • GPRO • Thu, Nov 26, 2009, 14:19 ET
Myriad's Not Doing Much
TraderMark • MYGN • Fri, Nov 6, 2009, 05:10 ET
Myriad Genetics: Horrendous Chart but Still Interesting
TraderMark • MYGN • Sun, Sep 27, 2009, 03:54 ET
Cleveland BioLabs Sees Promise in Cancer Drug to Negate Chemo Side Effects
ChinaBio Today • CBLI • Fri, Sep 11, 2009, 04:16 ET
Myriad Genetics' Home Run Earnings Report
TraderMark • MYGN • Thu, Aug 27, 2009, 05:44 ET
How Far Myriad Has Fallen: Is Information Leaking out?
TraderMark • MYGN • Thu, Jul 2, 2009, 04:34 ET
Myriad Genetics Spinoff Now in Place
John Clark • MYGN • Wed, Jun 17, 2009, 04:18 ET
Gene Patenting Will Hinder Biotechs and Drugmakers from Curing Maladies
Everyday Finance • MYGN • Thu, May 14, 2009, 06:14 ET

First Page
Previous Page
51 - 100 of 123
Next Page
Last Page